• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017
Conclusions Statin use remains suboptimal for the secondary ASCVD prevention, particularly in women and older patients, and following ischaemic stroke and PAD hospitalisations. Improving this would offer substantial benefits to population health at low cost.
Source: Heart - February 14, 2023 Category: Cardiology Authors: Thalmann, I., Preiss, D., Schlackow, I., Gray, A., Mihaylova, B. Tags: Open access Healthcare delivery, economics and global health Source Type: research

Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
CONCLUSIONS: Compared with statin monotherapy, ezetimibe with statin therapy was cost-effective for secondary prevention of CHD and stroke and for primary prevention of these conditions in patients whose LDL-C level is ≥ 100 mg/dL and in patients with diabetes, taking into account a 90% cost reduction for ezetimibe. PMID: 28426345 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 22, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention
Commentary on: Pandya A, Sy S, Cho S, et al. Cost effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015;314: 142–50 . Context The American College of Cardiology American Heart Association (ACC/AHA) cholesterol guidelines replaced the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) in 2013,1 a change that was accompanied by significant controversy.2 Notable among the criticisms was that the pooled cohort equations (PCE) overestimates risk and coupled with the relatively lenient risk threshold (10-year PCE &g...
Source: Evidence-Based Medicine - November 24, 2015 Category: Internal Medicine Authors: Yeboah, J. Tags: Health policy, Epidemiologic studies, Drugs: cardiovascular system, Neuromuscular disease, Stroke, Ischaemic heart disease, Musculoskeletal syndromes, Health economics, Health service research Economic analysis Source Type: research

Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome
Commentary on: Cannon CP, Blazing MA, Giugliano RP, et al., IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387–97. Context Use of statin therapy to treat dyslipidemia in patients with established coronary artery disease is the standard of care worldwide. Given the negative results of a number of trials that tested the use of adjuvant lipid-lowering therapies against a statin background, there has been great scepticism about whether or not non-statin drugs provide incremental benefit.1–3 Ezetimibe inhibits the absorption of both dietary and bili...
Source: Evidence-Based Medicine - September 24, 2015 Category: Internal Medicine Authors: Toth, P. P. Tags: Health policy, Epidemiologic studies, Genetics, Immunology (including allergy), Vaccination / immunisation, Stroke, Diet, Ischaemic heart disease, Health economics, Health service research, Lipid disorders Therapeutics/Prevention Source Type: research

Could exercise be as effective as medication?
Conclusion The researchers found that there are very few trials that directly compare exercise with drug therapy for any condition. They were only able to find enough trials to be able to analyse results for four major conditions. They found that exercise reduced death rates for people after a stroke (although this analysis has limitations and should be interpreted cautiously), and that drug therapy with diuretics improved death rates for people with heart failure. They did not find any difference between exercise and drug therapy for death rates after a heart attack or in people with pre-diabetes. There were several limit...
Source: NHS News Feed - October 2, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Heart/lungs Medication Source Type: news